Description: Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis or fungal nail infection. The company also provides drugs for protein misfolding diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota, as well as UV-light disinfection technology solutions. In addition, it provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.
Home Page: malinplc.com
The Lennox Building
Dublin,
D02 FK02
Ireland
Phone:
353 1 901 5700
Officers
| Name | Title |
|---|---|
| Mr. Darragh Fergal Lyons | CEO & Exec. Director |
| Andrea Stafford | Head of Fin. |
| Jessica Bergin | Director of Investor Relations & External Reporting |
| Dr. Andrew C. von Eschenbach M.D. | Chief Medical Adviser |
| Ms. Fiona Dunlevy | Company Sec. |
Exchange: IR
Country: IE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 51.8571 |
| Price-to-Book MRQ: | 1.3755 |
| Price-to-Sales TTM: | 6.1789 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |